Earnings Feed
Start Free
Home/Filings/4/0001179110-09-012864
4//SEC Filing

PEPIN RONALD 4

Accession 0001179110-09-012864

CIK 0000874255other
View on SEC.govCompany Profile

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 4:04 PM ET

Size

38.6 KB

Accession

0001179110-09-012864

Insider Transaction Report

Form 4
Period: 2009-09-01
MEDAREX INCMEDX
PEPIN RONALD
SVP, Bus. Dev.
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−50,000$800,000→ 0 total
    Exercise: $7.16Exp: 2013-10-13→ Common Stock (50,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−50,000$800,000→ 0 total
    Exercise: $14.89Exp: 2011-09-18→ Common Stock (50,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−53,400$854,400→ 0 total
    Exercise: $3.72Exp: 2019-03-04→ Common Stock (53,400 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh−17,800$284,800→ 0 total
    → Common Stock (17,800 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh−17,800$284,800→ 0 total
    → Common Stock (17,800 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−45,000$720,000→ 0 total
    Exercise: $5.61Exp: 2014-07-25→ Common Stock (45,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−100,000$1,600,000→ 0 total
    Exercise: $8.11Exp: 2012-07-10→ Common Stock (100,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−47,916$766,656→ 0 total
    Exercise: $14.61Exp: 2012-02-18→ Common Stock (47,916 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−60,000$960,000→ 0 total
    Exercise: $6.33Exp: 2013-09-07→ Common Stock (60,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−70,000$1,120,000→ 0 total
    Exercise: $14.92Exp: 2017-05-16→ Common Stock (70,000 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh−10,048$160,768→ 0 total
    → Common Stock (10,048 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−53,400$854,400→ 0 total
    Exercise: $9.07Exp: 2018-03-02→ Common Stock (53,400 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh−5,655$90,480→ 0 total
    → Common Stock (5,655 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−2,084$33,344→ 0 total
    Exercise: $14.61Exp: 2012-02-18→ Common Stock (2,084 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−100,000$1,600,000→ 0 total
    Exercise: $9.90Exp: 2015-09-05→ Common Stock (100,000 underlying)
Footnotes (20)
  • [F1]This option was canceled in the merger in exchange for a cash payment of $2,896.76, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F10]This option was canceled in the merger in exchange for a cash payment of $370,329.00, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F11]This option was canceled in the merger in exchange for a cash payment of $655,752.00, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F12]Each restricted stock unit represents a contingent right to receive one (1) share of Medarex, Inc. common stock.
  • [F13]This restricted stock unit was canceled in the merger in exchange for a cash payment of $213,600.00, based on the merger consideration ($16 per share) pursuant to a Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F14]This restricted stock unit was canceled in the merger in exchange for a cash payment of $284,800.00, based on the merger consideration ($16 per share) pursuant to a Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F15]This restricted stock unit was canceled in the merger in exchange for a cash payment of $160,768.00, based on the merger consideration ($16 per share) pursuant to a Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F16]This restricted stock unit was canceled in the merger in exchange for a cash payment of $90,480.00, based on the merger consideration ($16 per share) pursuant to a Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F17]Receipt of the restricted stock units was deferred until March 5, 2016.
  • [F18]Receipt of the restricted stock units was deferred until February 7, 2013.
  • [F19]Receipt of the restricted stock units was deferred until February 7, 2010.
  • [F2]This option was canceled in the merger in exchange for a cash payment of $442,250.51, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F20]The restricted stock units vested ratably over four years beginning on March 3, 2008.
  • [F3]This option was canceled in the merger in exchange for a cash payment of $467,667.01, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F4]This option was canceled in the merger in exchange for a cash payment of $610,000.00, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F5]This option was canceled in the merger in exchange for a cash payment of $55,500.00, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F6]This option was canceled in the merger in exchange for a cash payment of $66,603.24, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F7]This option was canceled in the merger in exchange for a cash payment of $789,000.00, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F8]This option was canceled in the merger in exchange for a cash payment of $580,200.00, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.
  • [F9]This option was canceled in the merger in exchange for a cash payment of $75,950.00, represening the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between the issuer and Bristol-Myers Squibb.

Documents

1 file

Issuer

MEDAREX INC

CIK 0000874255

→
Entity typeother

Related Parties

1
  • filerCIK 0001214504

Filing Metadata

Form type
4
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 4:04 PM ET
Size
38.6 KB
View on SEC.gov